Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23932615 | 0.95 | ERN1 (0.46) | ERN1LMNAFDPSALDH1A1MAOB | |
| SCHEMBL12223477 | 0.85 | LMNA (0.50) | ERN1LMNAFDPSALDH1A1MAOB | |
| SCHEMBL1913197 | 0.82 | LMNA (0.54) | ERN1LMNAFDPSALDH1A1TUBB1 | |
| SCHEMBL28360604 | 0.82 | LMNA (0.48) | ERN1LMNAMAOB | |
| SCHEMBL3547230 | 0.81 | ERN1 (0.45) | ERN1LMNAFDPSALDH1A1MAOB | |
| SCHEMBL426335 | 0.80 | ALDH1A1 (0.63) | ERN1ALDH1A1MAOBMAPTTUBB1 | |
| SCHEMBL421566 | 0.80 | LMNA (0.49) | ERN1LMNATSHR | |
| SCHEMBL23932614 | 0.80 | ERN1 (0.44) | ERN1LMNAFDPSALDH1A1MAOB | |
| SCHEMBL1913198 | 0.78 | PPARA (0.52) | ERN1LMNAALDH1A1 | |
| SCHEMBL6317669 | 0.77 | PTPN1 (0.48) | ERN1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1828169-A2 | UREA INHIBITORS OF MAP KINASES | Locus Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060167247-A1 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| WO-2006062982-A2 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| US-7038054-B1 | Diazabicyclononane scaffold for combinatorial synthesis | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050047976-A1 | Method and apparatus for solid or solution phase reaction under ambient or inert conditions | SENOMYX, INC. | 2005-03-03 | — | — | US | disclosed |
| US-6642417-B2 | Solid phase synthesis; libraries | PHARMACOPEIA DRUG DISCOVERY, INC. | 2003-11-04 | — | — | US | disclosed |
| WO-2002060585-A1 | METHOD AND APPARATUS FOR SOLID OR SOLUTION PHASE REACTION UNDER AMBIENT OR INERT CONDITIONS | SENOMYX, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| US-6310244-B1 | DEMONSTRATES THE ABILITY TO WITHSTAND MANY COMMON REACTION CONDITIONS AND YET IS CLEAVABLE UNDER RELATIVELY MILD CONDITIONS. | PHARMACOPEIA, INC. | 2001-10-30 | — | — | US | disclosed |
| US-20010025084-A1 | Photocleavable and acid cleavable linkers for combinatorial chemistry | PHARMACOPEIA, LLC | 2001-09-27 | — | — | US | disclosed |
| US-6093799-A | Universal linker for combinatorial synthesis | PHARMACOPEIA, INC. (US) | 2000-07-25 | — | — | US | disclosed |
| WO-2000005197-A1 | PHOTOCLEAVABLE AND ACID CLEAVABLE LINKERS FOR COMBINATORIAL CHEMISTRY | PHARMACOPEIA, INC. (US) | 2000-02-03 | — | — | WO | disclosed |
| US-6008321-A | Universal linker for combinatorial synthesis | PHARMACOPEIA, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1999047498-A1 | UNIVERSAL LINKER FOR COMBINATORIAL SYNTHESIS | PHARMACOPEIA, INC. (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1999039207-A1 | ACID CLEAVABLE PHENOXYALKYL LINKER FOR COMBINATORIAL SYNTHESIS | PHARMACOPEIA, INC. (US) | 1999-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167247-A1 | Urea inhibitors of MAP kinases | MAPK1, MAP3K1, MAP3K20 | ERN1 121/4885LMNA 2936/4885FDPS 1978/4885 |
| US-20010025084-A1 | Photocleavable and acid cleavable linkers for combinatorial chemistry | CCNE1, CCNB1, CDK1 | ERN1 1096/4885LMNA 1398/4885FDPS 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.